antagonista glp 1 GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes Agonista del receptor GLP 1:

A ACE inhibitors or angiotensin receptor blockers (ARBs) are recommended first-line therapy for hypertension in people with diabetes and coronary artery disease (CAD)

"While GLP-1 medications affect gastrointestinal tract motility, their quantified impact may not be as significant as previously assumed, said corresponding author, Dr Walter Chan, director of the Center of Gastrointestinal Motility and a physician in the Brigham's Division of Gastroenterology, Hepatology and Endoscopy

NCCN clinical practice guidelines in oncology: thyroid carcinoma [Internet]

**Patients without diabetes and with BMI 30, or BMI 27 plus a weight-related condition, lost an average of 20% of their body weight by 1 year in a 72-week trial studying the highest maintenance dose of Zepbound (15 mg), when paired with diet and exercise changes (compared to 3% with diet and exercise alone)